Comparison of DAAs(Direct Acting Antivirals) and interferon-based triple therapy for hepatitis C after treatment of hepatocelluler carcinoma.
Not Applicable
- Conditions
- Hepatitis C after treatment for hepatocelluler carcinoma.
- Registration Number
- JPRN-UMIN000014971
- Lead Sponsor
- Musashino Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients judged by doctor that participation in the study is improper
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of recurrence survival rate
- Secondary Outcome Measures
Name Time Method